LTR Pharma Multi-Market Strategy and Regulatory Update
By API User
26 March 2025 – LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to provide an update to the Company’s commercial and regulatory processes, highlighting the strong progress that has been made toward the global commercialisation and approvals for its innovative intranasal erectile dysfunction (ED) treatment, SPONTAN®. Highlights Successful FDA pre-IND meeting has … Continued